Acorda Therapeutics: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Acorda Therapeutics}} | ||
'''Acorda Therapeutics''' is | [[File:Acorda_Therapeutics_logo.svg|thumb|right|Logo of Acorda Therapeutics]] | ||
'''Acorda Therapeutics''' is a [[biotechnology]] company that develops therapies for [[neurological disorders]]. The company is headquartered in [[Ardsley, New York]]. | |||
==History== | ==History== | ||
Acorda Therapeutics was founded in 1995 by [[Ron Cohen]], M.D., with the | Acorda Therapeutics was founded in 1995 by [[Ron Cohen]], M.D., with the mission to develop therapies that restore function and improve the lives of people with neurological disorders. The company initially focused on developing treatments for [[spinal cord injury]] and later expanded its research to include other neurological conditions such as [[multiple sclerosis]] (MS) and [[Parkinson's disease]]. | ||
==Products== | ==Products== | ||
Acorda Therapeutics | Acorda Therapeutics is known for developing several key products in the field of neurology: | ||
* '''Ampyra''' | * '''[[Ampyra]] (dalfampridine)''': A medication approved by the [[Food and Drug Administration]] (FDA) to improve walking in patients with multiple sclerosis. It works by blocking [[potassium channels]] on the surface of [[nerve cells]], which helps improve nerve signal conduction. | ||
* '''Inbrija | * '''Inbrija (levodopa inhalation powder)''': An inhaled form of [[levodopa]] used to treat "off" episodes in patients with Parkinson's disease who are already taking a [[carbidopa]]/levodopa regimen. It provides rapid relief from symptoms by delivering levodopa directly to the bloodstream through the lungs. | ||
==Research and Development== | ==Research and Development== | ||
Acorda Therapeutics | Acorda Therapeutics invests heavily in [[research and development]] to discover new treatments for neurological disorders. The company's R&D efforts focus on innovative drug delivery systems and novel therapeutic targets. Acorda collaborates with academic institutions and other biotechnology companies to advance its research pipeline. | ||
==Corporate Structure== | ==Corporate Structure== | ||
Acorda Therapeutics operates as a publicly traded company on the [[NASDAQ]] stock exchange under the ticker symbol "ACOR." The company is led by a team of executives with | Acorda Therapeutics operates as a publicly traded company on the [[NASDAQ]] stock exchange under the ticker symbol "ACOR." The company is governed by a board of directors and led by a team of executives with extensive experience in the biotechnology and pharmaceutical industries. | ||
==Community Involvement== | ==Community Involvement== | ||
Acorda Therapeutics is committed to supporting the neurological community through various initiatives, | Acorda Therapeutics is committed to supporting the neurological community through various initiatives. The company sponsors educational programs, patient advocacy groups, and research foundations to raise awareness and improve the quality of life for individuals with neurological disorders. | ||
==Related pages== | ==Related pages== | ||
* [[Biotechnology]] | * [[Biotechnology]] | ||
* [[ | * [[Neurological disorder]] | ||
* [[Multiple sclerosis]] | * [[Multiple sclerosis]] | ||
* [[Parkinson's disease]] | * [[Parkinson's disease]] | ||
* [[Spinal cord injury]] | |||
[[Category:Biotechnology companies]] | |||
[[Category:Pharmaceutical companies of the United States]] | |||
[[Category: | |||
[[Category:Companies based in New York (state)]] | [[Category:Companies based in New York (state)]] | ||
[[Category: | [[Category:Companies established in 1995]] | ||
Latest revision as of 06:19, 16 February 2025
Acorda Therapeutics is a biotechnology company that develops therapies for neurological disorders. The company is headquartered in Ardsley, New York.
History[edit]
Acorda Therapeutics was founded in 1995 by Ron Cohen, M.D., with the mission to develop therapies that restore function and improve the lives of people with neurological disorders. The company initially focused on developing treatments for spinal cord injury and later expanded its research to include other neurological conditions such as multiple sclerosis (MS) and Parkinson's disease.
Products[edit]
Acorda Therapeutics is known for developing several key products in the field of neurology:
- Ampyra (dalfampridine): A medication approved by the Food and Drug Administration (FDA) to improve walking in patients with multiple sclerosis. It works by blocking potassium channels on the surface of nerve cells, which helps improve nerve signal conduction.
- Inbrija (levodopa inhalation powder): An inhaled form of levodopa used to treat "off" episodes in patients with Parkinson's disease who are already taking a carbidopa/levodopa regimen. It provides rapid relief from symptoms by delivering levodopa directly to the bloodstream through the lungs.
Research and Development[edit]
Acorda Therapeutics invests heavily in research and development to discover new treatments for neurological disorders. The company's R&D efforts focus on innovative drug delivery systems and novel therapeutic targets. Acorda collaborates with academic institutions and other biotechnology companies to advance its research pipeline.
Corporate Structure[edit]
Acorda Therapeutics operates as a publicly traded company on the NASDAQ stock exchange under the ticker symbol "ACOR." The company is governed by a board of directors and led by a team of executives with extensive experience in the biotechnology and pharmaceutical industries.
Community Involvement[edit]
Acorda Therapeutics is committed to supporting the neurological community through various initiatives. The company sponsors educational programs, patient advocacy groups, and research foundations to raise awareness and improve the quality of life for individuals with neurological disorders.
